CEFCLIDIN IN THE TREATMENT OF PATIENTS WITH SURGICAL INFECTIONS

• Published in: CHEMOTHERAPY Vol. 40; no. Supplement4; pp. 531 - 540
• Main Authors: Morimoto, Ken, Kinoshita, Hiroaki, Nakatani, Shuichi, Sakai, Katsuji, Fujimoto, Mikio, Ohno, Koh-ichi, Ueda, Takami, Hirata, Sanae, Muramatsu, Hideyuki, Miyamoto, Toh-u, Yamazaki, Osamu, Morimoto, Yuzuru
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 30-09-1992
• Subjects: Cefclidin; Cephems
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.40.Supplement4_531

We gave cefclidin (CFCL) to three patients undergoing biliary drainage and studied its pharmacokinetics. We also treated 22 surgical infections with this drug and evaluated its clinical efficacy in 20 of the infections. In the pharmacokinetic study, 1.0g was infused intravenously for 30 min. The peak levels in the plasma of the two patients, who consented to give blood samples were, 44.7 and 61.5μg/ml at 0.5 hour. The peak levels in the bile, 2.66, 11.9, 7.537μg/ml, were at 1 to 4 hours. Of the 20 infections, the clinical efficacy of the drug was excellent in 9, good in 6, fair in 4, and poor in 1, with an efficacy rate of 75%. The bacteriological response could be evaluated in 15 of the 20 infections. The bacteria were eradicated in 5 infections, they decreased in 4 infections, and they persisted in 6 infections. The bacteriological responses in 34 strains of 20 species of organisms isolated were evaluated. Eighteen strains (53%) were eradicated. The MICs could be calculated for 24 of the 34 bacterial strains isolated. Seventeen of the 32 strains had MICs lower than the peak plasma levels we found (MICs of 25, μg/ml or less). Eight of the 24 strains had MICs lower than the peak bile levels (MICs of less than 3.13, μg/ml). There were no serious side effects caused by this drug. CFCL is a promising drug for surgical infections including biliary tract infections.